Biolife Solutions Inc (BLFS) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Biolife Solutions Inc (BLFS) stock forecast summary
On Oct. 14, 2026, BLFS is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5171 stocks scored that day.
Biolife Solutions Inc is a small-cap company with a market capitalization of $1.89B. It ranks number 5 by market capitalization among the 30 Electromedical & Electrotherapeutic Apparatus issuers in our coverage with a current forecast. Its Net Margin of 56.4% is the highest of the 22 peers that report one. Its D/E Ratio of 0.07x is the lowest of the 25 peers that report one.
A per-ticker accuracy statistic for BLFS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BLFS included.
Follow BLFS freeBLFS price chart and AI forecast
How BLFS ranks among 5171 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Biolife Solutions Inc (BLFS) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Electromedical & Electrotherapeutic Apparatus peers listed below that report each metric.
Valuation & Market
| Metric | BLFS | Rank |
|---|---|---|
| Market Cap | $1.89B | 5/30 |
| P/E Ratio | 32.57x | 2/10 |
| P/B Ratio | 4.50x | 10/23 |
| EPS | $1.14 | – |
| Book Value/Share | $8.59 | – |
| Revenue/Share | $2.10 | – |
Profitability & Margins
| Metric | BLFS | Rank |
|---|---|---|
| ROE | 13.8% | 5/19 |
| ROA | 13.0% | 3/24 |
| ROIC | 0.7% | 11/23 |
| Operating Margin | 2.9% | 8/28 |
| Net Margin | 56.4% | 1/22 |
| EBT Margin | 7.8% | 6/28 |
| Tax Rate | -526.2% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | BLFS | Rank |
|---|---|---|
| Current Ratio | 9.69x | 2/30 |
| Quick Ratio | 7.14x | 4/29 |
| D/E Ratio | 0.07x | 25/25 |
| Financial Leverage | 1.07x | 25/25 |
| Interest Coverage | 16.2x | 6/30 |
| Working Capital | $121M | 10/29 |
Cash Flow
| Metric | BLFS | Rank |
|---|---|---|
| Operating Cash Flow | $17M | 7/30 |
| OCF Growth YoY | 8.6% | 5/9 |
Operational Efficiency
| Metric | BLFS | Rank |
|---|---|---|
| Asset Turnover | 0.23x | 18/19 |
| Receivables Turnover | 9.7x | 5/20 |
| Fixed Assets Turnover | 6.8x | 14/20 |
| Days Sales Outstanding | 38 days | 16/20 |
Income Statement
| Metric | BLFS | Rank |
|---|---|---|
| Total Revenue | $102M | 7/19 |
| Operating Income | $2M | 8/30 |
| Net Income | $57M | 7/24 |
| R&D Expense | $8M | 15/28 |
| SG&A Expense | $98M | 10/26 |
Dividend & Shareholder Information
| Metric | BLFS | Rank |
|---|---|---|
| Shares Outstanding | 49M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $135M | 30.2% of assets |
| Cash & Short-term Investments | $24M | 5.4% of assets |
| Accounts Receivable | $11M | 2.4% of assets |
| Inventory | $36M | 8.0% of assets |
| Total Liabilities | $27M | 6.1% of assets |
| Short-term Debt | $11M | 2.6% of assets |
BLFS quarterly financials and insider trading
Biolife Solutions Inc (BLFS) industry peers
Companies classified under the same SEC industry code as Biolife Solutions Inc (Electromedical & Electrotherapeutic Apparatus): 32 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| BLFS Biolife Solutions Inc | ▶ | $1.89B |
| MDT Medtronic Plc | ▼ | $121.20B |
| ITGR Integer Holdings Corp | ▼ | $4.31B |
| LIVN Livanova Plc | ▼ | $4.27B |
| TMDX Transmedics Group, Inc. | ▲ | $2.45B |
| AXGN Axogen, Inc. | ▲ | $1.86B |
| CNMD Conmed Corp | ▼ | $1.40B |
| CBLL Ceribell, Inc. | ▲ | $961M |
| INMD Inmode Ltd. | ▼ | $814M |
| CV Capsovision, Inc | ▶ | $323M |
| ELMD Electromed, Inc. | ▼ | $229M |
| FOCL Edap Tms Sa | ▲ | $153M |
| VANI Vivani Medical, Inc. | ▶ | $104M |
| STXS Stereotaxis, Inc. | ▶ | $101M |
| NRXS Neuraxis, Inc | ▲ | $97M |
| HYPR Hyperfine, Inc. | ▲ | $77M |
| OM Outset Medical, Inc. | ▲ | $77M |
| ECOR Electrocore, Inc. | ▲ | $71M |
| POSC Positron Corp | ▲ | $53M |
| VASO Vaso Corp | ▲ | $51M |
| POCI Precision Optics Corporation, Inc. | ▲ | $48M |
| QTI Qt Imaging Holdings, Inc. | ▶ | $35M |
| ITOC Itonic Holdings Ltd | ▼ | $29M |
| GTHP Guided Therapeutics Inc | ▲ | $18M |
| IRIX Iridex Corp | ▲ | $14M |
| NDRA Endra Life Sciences Inc. | ▶ | $7M |
| ADMT Adm Tronics Unlimited, Inc. | ▶ | $3M |
| NXL Nexalin Technology, Inc. | ▼ | $2M |
| NUWE Nuwellis, Inc. | ▼ | $2M |
| ESMC Escalon Medical Corp | ▲ | $1M |
| HCIL Hongchang International Co., Ltd | ▼ | N/A |
| YBGJ Yubo International Biotech Ltd | ▶ | N/A |
Where BLFS sits on the market map
Biolife Solutions Inc (BLFS) stock news
Loading...
Biolife Solutions Inc (BLFS) stock forecast FAQ
What is the Biolife Solutions Inc (BLFS) stock forecast?
On Oct. 14, 2026, BLFS is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5171 stocks scored that day.
How accurate are Biolife Solutions Inc stock predictions?
A per-ticker accuracy statistic for BLFS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Biolife Solutions Inc forecasts updated?
Biolife Solutions Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Biolife Solutions Inc's industry peers?
32 issuers in our coverage, BLFS included, share the SEC industry code Electromedical & Electrotherapeutic Apparatus. The largest are: Medtronic Plc (MDT), Integer Holdings Corp (ITGR), Livanova Plc (LIVN), Transmedics Group, Inc. (TMDX), Axogen, Inc. (AXGN), Conmed Corp (CNMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.